US Dollar vs Yen

登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

登録

PEPG

PepGen (PEPG)

PepGen Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:PEPG

1 2 3 4 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/03/14	05 : 05	GlobeNewswire Inc.	PepGen to Participate in Upcoming Investor Conferences	NASDAQ:PEPG	PepGen Inc
2024/03/13	20 : 00	GlobeNewswire Inc.	PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	NASDAQ:PEPG	PepGen Inc
2024/03/07	06 : 23	Edgar (US Regulatory)	Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]	NASDAQ:PEPG	PepGen Inc
2024/03/07	06 : 01	GlobeNewswire Inc.	PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	NASDAQ:PEPG	PepGen Inc
2024/03/07	06 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2024/03/04	21 : 27	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2024/03/04	21 : 00	GlobeNewswire Inc.	PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	NASDAQ:PEPG	PepGen Inc
2024/03/02	07 : 49	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PEPG	PepGen Inc
2024/03/02	07 : 33	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PEPG	PepGen Inc
2024/03/02	07 : 29	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:PEPG	PepGen Inc
2024/02/20	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2024/02/20	22 : 00	GlobeNewswire Inc.	PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	NASDAQ:PEPG	PepGen Inc
2024/02/08	06 : 55	Edgar (US Regulatory)	Form 424B5 - Prospectus [Rule 424(b)(5)]	NASDAQ:PEPG	PepGen Inc
2024/02/07	21 : 36	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2024/02/07	21 : 30	GlobeNewswire Inc.	PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock	NASDAQ:PEPG	PepGen Inc
2024/01/17	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2024/01/17	21 : 00	GlobeNewswire Inc.	Mary Beth DeLena Joins PepGen as General Counsel and Secretary	NASDAQ:PEPG	PepGen Inc
2024/01/08	21 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2024/01/08	21 : 00	GlobeNewswire Inc.	PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping	NASDAQ:PEPG	PepGen Inc
2023/12/18	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2023/12/18	22 : 00	GlobeNewswire Inc.	PepGen Announces First Patient Dosed in Phase 1 FREEDOM-DM1 Clinical Trial of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)	NASDAQ:PEPG	PepGen Inc
2023/11/15	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2023/11/15	22 : 00	GlobeNewswire Inc.	PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors	NASDAQ:PEPG	PepGen Inc
2023/11/08	22 : 30	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:PEPG	PepGen Inc
2023/11/08	22 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2023/11/08	22 : 00	GlobeNewswire Inc.	PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments	NASDAQ:PEPG	PepGen Inc
2023/10/12	20 : 52	Dow Jones News	FDA Lifts Hold on PepGen's New Drug Application for Dystrophy Treatment	NASDAQ:PEPG	PepGen Inc
2023/10/12	20 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:PEPG	PepGen Inc
2023/10/12	20 : 00	GlobeNewswire Inc.	PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1)	NASDAQ:PEPG	PepGen Inc
2023/09/28	05 : 16	GlobeNewswire Inc.	PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society and the World Congress of Neurology	NASDAQ:PEPG	PepGen Inc

Showing the most relevant articles for your search:NASDAQ:PEPG

1 2 3 4 次へ >>

American Express

US Dollar vs Sterling

Bank of America

JP Morgan Chase

US Dollar vs Euro

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約